Janssen not getting too down on Spravato by keeping data coming

10 July 2023

There was plenty of hype and hope attached to the arrival of Spravato (esketamine nasal spray) as a treatment for depression when it first started to be launched in major markets more than four years ago.

Since then, sales have not exactly shot through the roof, at a modest $131 million for the first quarter of 2023, with reimbursement issues and doubts about efficacy among the reasons for the slow uptake.

But drug developer Janssen, a subsidiary of Johnson & Johnson (NYSE: JNJ), is keeping the data coming, and has presented further results from ESCAPE-TRD, a Phase IIIb trial comparing flexibly-dosed Spravato with quetiapine extended-release, both in combination with a continuing selective serotonin reuptake inhibitor or serotonin and norepinephrine reuptake inhibitor, in treatment-resistant depression (TRD).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK